For a consideration of USD 625 million
Claris Lifesciences announced that it has entered into definitive agreements with Baxter International for the sale of its global generic injectables business for a total gross consideration of USD 625 million.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
